在COVID-19 ARDS中,托西利祖马布对呼吸系统亚表型的免疫生物学的影响
Emma Rademaker1,2, Daan F L Filippini3, Jelle L G Haitsma Mulier4,5
1Department of Intensive Care Medicine, UMC Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands. e.rademaker-2@umcutrecht.nl.
Intensive care medicine experimental
|July 9, 2025
概括
托西利祖马布显著影响COVID-19急性呼吸困扰综合征 (ARDS) 患者的炎症标志物. 与托西利祖马布相比,呼吸系统亚型具有较小的影响,这表明亚型不应该指导治疗决策.
科学领域:
- 关键护理医学 关键护理医学
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
背景情况:
- 在COVID-19急性呼吸窘迫综合征 (ARDS) 患者中,两种截然不同的纵向呼吸道亚型表现出动态的免疫生物学变化.
- 了解这些亚表型和像托西利祖马布这样的免疫调节疗法之间的相互作用,对于优化患者护理至关重要.
研究的目的:
- 研究呼吸系统亚表型和托西利祖马布治疗对ARDS患者炎症反应和临床结果的独立和联合作用.
- 为了确定呼吸系统亚表型是否会影响托西利祖马布的疗效.
主要方法:
- 分析了来自COVID-19生物库的720名患者,这些患者被入住了入侵性机械通风的ICU.
- 将患者分为"低功率"和"高功率"的呼吸系统亚表型,根据机械功率,分钟体积和呼吸器比率进行分类.
- 评估与子表型和托西利祖马布治疗相关的血生物标志物 (SP-D,血栓模块素,TNF-RI,IL-6,血管蛋白-2) 和死亡率.
主要成果:
- 高功率亚表型在输管时显示出SP-D,血栓模块素和TNF-RI的度略高.
- 托西利祖马布治疗对IL-6和 ангиопоэтин-2水平的影响比呼吸系统亚表型更大.
- 呼吸系统亚表型没有改变托西利祖马布和死亡率之间的关联.
结论:
- 虽然呼吸道亚表型对托西利祖马布的反应不同,但与药物的整体效果相比,这些差异很小.
- 在ARDS患者中,托西利祖马布治疗决策不应基于呼吸系统亚表型.
相关概念视频
01:20COPD: Pathogenesis and Clinical Features
533
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
533
01:26Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
01:19Antiasthma Drugs: Leukotriene Modifiers
489
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
489
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
471
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
471
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
398
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
398
01:26COPD: Management Using Bronchodilators and Corticosteroids
322
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
322